Glycomimetics INC Form 4 insider transactions
GlycoMimetics, Inc. is set to acquire Crescent Biopharma, Inc. through a merger agreement, aiming to advance cancer therapy innovation.
Crescent Biopharma announces key executive appointments as it progresses towards a reverse merger with GlycoMimetics and advances its oncology pipeline.
425: GlycoMimetics Faces Setbacks: Apollomics Agreement Terminated, Board and Executive Leadership Resign
GlycoMimetics reports the termination of its Apollomics collaboration agreement, resignations of multiple board members, and the departure of its CEO and CFO.
GlycoMimetics and Crescent Biopharma amend their merger agreement, altering the financing structure and SEC filing process while maintaining the expected exchange ratio and ownership percentages.
Invus Public Equities, L.P. reports the sale of GlycoMimetics Inc. common stock in two transactions on August 7 and 8, 2024.
Invus Public Equities, L.P. reports selling shares of GlycoMimetics Inc. at weighted average prices of $0.1884 and $0.1828, reducing its holdings.
Invus Public Equities, L.P., a 10% owner of GlycoMimetics Inc, reports selling shares of common stock in two transactions on August 1st and 2nd, 2024.
Invus Public Equities, L.P. reports the sale of GlycoMimetics Inc. shares across multiple transactions between July 26 and July 30, 2024.
Edwin Rock, Chief Medical Officer of GlycoMimetics, recently purchased a significant number of shares in the company, signaling confidence in its future.
Brian M. Hahn, SVP Finance and CFO of GlycoMimetics, Inc., recently purchased 17,500 shares of the company's common stock on the open market.
A Form 4 filing reveals that GlycoMimetics director Scott Koenig acquired 40,000 stock options on May 1, 2024.
Mark Alan Goldberg, a director of GlycoMimetics, Inc., acquired stock options for 40,000 shares on May 1, 2024.
Director Timothy R. Pearson of GlycoMimetics, Inc. reports acquisition of stock options.
Director Rachel K. King acquired stock options for 40,000 shares of GlycoMimetics, Inc. on May 1, 2024.
Patricia S. Andrews, a director of GlycoMimetics Inc., acquired stock options for 40,000 shares on May 1, 2024.
Director Scott Thomas Jackson acquires stock options in GlycoMimetics, Inc.
Director Daniel M. Junius acquired stock options for 40,000 shares of GlycoMimetics Inc. at an exercise price of $1.62 on May 1, 2024.
Director Daniel M. Junius acquired 5,209 shares of GlycoMimetics Inc. common stock on March 29, 2024, in lieu of board and committee retainer fees.
Director Rachel K. King acquired 3,334 shares of GlycoMimetics stock on March 29, 2024, in lieu of $10,000 in board and committee retainer fees.
Mark Alan Goldberg, a director at GlycoMimetics, acquired 4,584 shares of common stock in lieu of board and committee retainer fees.